leadf
logo-loader
viewPolynovo Ltd
(
ASX:PNV
)

Polynovo follows swift re-rating with a capital raising

The halt will remain in place until Tuesday 25th September 2017.

1506037874_rsz_shutterstock_276800108.jpg
The company's shares are in pre-open

Polynovo Ltd's (ASX:PNV) shares last traded at $0.285, or around 60% higher than a month ago, with the company receiving a positive re-rating following its first U.S. sales of NovoSorb BTM™

NovoSorb is a tissue scaffold that facilitates the regeneration of the dermis when it has been lost or damaged through trauma, burns, surgery or wounding.

Polynovo is now heading to market with a capital raising, and the ASX has granted a trading halt to prepare.

The halt will remain in place until the opening of trade on Tuesday 25th September 2017, or earlier if an announcement is made to the market.

Quick facts: Polynovo Ltd

Follow
ASX:PNV

Price: 1.945 AUD

Market Cap: $1.29 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

MGC Pharmaceuticals: Continuous global breakthroughs as progress accelerates

Proactive Research Analyst Ed Stacey presents his analysis on MGC Pharmaceuticals (LON:MXC).  The company recently announced that it has received a UK import permit for CannEpil+, which is MGC’s cannabis-derived therapy for refractory epilepsy, to be used initially on a compassionate access...

4 hours, 36 minutes ago

2 min read